AprilBio Submits Securities Registration Statement for KOSDAQ Listing

July 13-14 Demand Forecast, July 19-20 Subscription
Offering Price 20,000~23,000 KRW

[Asia Economy Reporter Lee Gwan-joo] AprilBio announced on the 21st that it has submitted a securities registration statement to the Financial Services Commission and officially started the public offering process for listing on KOSDAQ.

AprilBio is a protein (antibody) therapeutic development company targeting autoimmune diseases, inflammatory diseases, and cancer by utilizing the platform technology 'SAFA (Anti-Serum Albumin Fab)', which extends the half-life of drugs (the time it takes for the drug concentration to decrease from its peak to half), and the 'antibody library' (HuDVFab, Human naive Fab antibody library) technology that discovers antibodies matching target antigens.

Last year, it succeeded in licensing the APB-A1 pipeline based on the SAFA platform technology to the Danish global pharmaceutical company Lundbeck. The deal is worth approximately 540 billion KRW (excluding royalties), the largest amount among unlisted biotech companies in Korea.

For this listing, AprilBio plans to offer 1.62 million shares. The expected public offering price is between 20,000 and 23,000 KRW, with a total public offering amount of 32.4 billion to 37.3 billion KRW. The demand forecast will be conducted over two days from July 13 to 14, followed by subscription on the 19th and 20th, and the company is scheduled to enter the KOSDAQ market on the 28th of the same month. NH Investment & Securities is in charge of the listing underwriting.

Cha Sang-hoon, CEO of AprilBio, said, "AprilBio has achieved remarkable growth by developing differentiated new drug candidates through the core technology 'SAFA' with infinite scalability," adding, "After listing, we will continue to focus on developing competitive pipelines to ensure stable profit generation and enhance corporate value."

This content was produced with the assistance of AI translation services.